# OnCo record endo (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/endo/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "endo" ;
  schema:name "Endo (now Keenova Therapeutics and Par Health)"@en ;
  schema:alternateName "Endo International plc"@en, "Endo Pharmaceuticals"@en, "Endo USA Inc., a Keenova Therapeutics Company"@en, "Endo USA Inc."@en, "Keenova Therapeutics"@en, "Par Pharmaceutical, Inc."@en, "Par Pharmaceutical"@en, "Par Health"@en ;
  schema:description "Endo was a specialty and generics pharmaceutical company, one of the busiest industry sponsors of phase 3 cancer trials on ClinicalTrials.gov; after merging with Mallinckrodt it became Keenova Therapeutics, with its generics arm spun off as Par Health."@en ;
  schema:url <https://onco.cc/companies/endo/>, <https://www.endo.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endo_International> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5376211> ;
  schema:citation <https://www.endo.com>, <https://clinicaltrials.gov/search?lead=Endo%20International%20plc>, <https://www.wikidata.org/wiki/Q5376211>, <https://en.wikipedia.org/wiki/Valrubicin> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "IE" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/bcg-and-intravesical-therapy/> ;
  onco:drugs <https://onco.cc/drugs/valrubicin/>, <https://onco.cc/drugs/histrelin/>, <https://onco.cc/drugs/megestrol/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .